USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Japan as represented by Director General of National Institute of Infectious Diseases

Q: Where does Japan as represented by Director General of National Institute of Infectious Diseases rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Japan as represented by Director General of National Institute of Infectious Diseases ranks #19,948 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

Q: How is the Japan as represented by Director General of National Institute of Infectious Diseases patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 14 granted patents across 11 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Japan ranks #19,948 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 11 technology areas.

#19,948
of 49,997 US assignees by volume: Top 29%
by Innovation Score (42.9/100): 14.2
avg claims per patent: -25%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R19948 · Foreign Corporation #19,948 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 14 grants
MID-PACK #19,948/49,997
PHOTO-FINISH J VAN Zoest Beheer B V
CPC-FOCUS A61P · 11 areas
INNOV-PAR 42.9/100
CLAIMS-RICH 14.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -25% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: J. VAN Zoest Beheer B.V. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Japan’s 42.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.4 pts (22%) Velocity 13.3 pts (31%) Breadth 11.7 pts (27%) Claim depth 8.5 pts (20%)

Qualcomm Incorporated · highest

85
Japan as represented… · this assignee

43
3D Lighting… · lowest

7

What this shows Japan's Innovation Score is 42.9/100 (top 29% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Japan?

Each dot is one of Japan’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Japan’s own 14.2 claims/patent is ABOVE the 10.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Japan vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Japan's grants concentrate

Japan as represented by Director General of National Institute of Infectious Diseases is a focused PatentsView assignee: 11 CPC subclasses with 85.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (4 grants) versus a trough of 1 in 2020. By volume, Japan sits between J. VAN Zoest Beheer B.V. and JM Energy Corporation.

Japan's three-year grant acceleration

Japan as represented by Director General of National Institute of Infectious Diseases shows 4 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

J VAN Zoest Behee…

14
J F R Enterprises

14
Jamf Software

14
Japan Radio

14
Jenax

14
Jiangsu Dongcheng…

14
Jiangsu Shemar El…

14
JM Energy

14
Japan as represen… ◀

14

What this shows Japan holds 14 patents at rank #19,947, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Japan

By rank, the assignees closest to #19,947 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Japan's primary technology class.

Japan's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 29% higher than 71% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Japan as represented by Director General of National Institute of Infectious Diseases patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	28.6%
2016	2	14.3%
2017	2	14.3%
2020	1	7.1%
2021	1	7.1%
2022	2	14.3%
2023	1	7.1%
2024	1	7.1%

Which technologies does Japan as represented by Director General of National Institute of Infectious Diseases patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 12

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 10

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

C07K - Peptides 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

C08F - Macromolecular Compounds Obtained BY Reactions Only Involving Carbon-to-carbon Unsaturated Bonds 1

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 1

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 1

C08L - Compositions OF Macromolecular Compounds 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Japan as represented by Director General of National Institute of Infectious Diseases's patent record in context - here's where to go next.

Japan as represented by Director General of National Institute of Infectious Diseases's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 85.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #19,948 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Japan as represented by Director General of National Institute of Infectious Diseases against J. VAN Zoest Beheer B.V., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 42.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.